Lykos Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for MDMA-Assisted Therapy for PTSD

PDUFA date is August 11, 2024 If approved, this would be the first MDMA-assisted therapy and psychedelic-assisted therapy SAN JOSE, Calif., Feb. 9, 2024 /PRNewswire/ — Lykos Therapeutics (formerly MAPS Public Benefit Corporation) (“Lykos”), a company dedicated to transforming mental…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks